Cardium Reports on First Quarter 2008 Highlights and Financi...( SAN DIEGO May 9 /- Cardium Therap...)

SAN DIEGO, May 9 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) today reported recent highlights and developments, as well as financial results for its first quarter ended March 31, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

Highlights and Recent Developments

-- European commercialization agreement with Euromed Medizinisch GmbH

(Euromed) for InnerCool's CoolBlue(TM) surface temperature modulation

system and RapidBlue endovascular system. Euromed, a leading

distributor of cardiology medical products will have exclusive

marketing, sales and distribution rights in Austria, Germany and

Switzerland for InnerCool's portfolio of temperature modulation

systems.

-- Australian distribution agreement with Lifehealthcare Pty Ltd., one of

Australia's leading medical device distributors and health service

providers. Under the agreement, Lifehealthcare has the exclusive

rights to market, sell and distribute InnerCool's CoolBlue and

RapidBlue temperature modulation systems in Australia and New Zealand.

-- Publication by BioMed Central (BMC) Cardiovascular Disorders

(2008, 8:7, April 10, 2008) of positive findings from a preclinical

study conducted by researchers at Lund University Hospital in Sweden

demonstrating a new and expanded benefit of early rapid cooling for the

potential treatment of acute myocardial infarction (heart attack). The

same researchers are currently recruiting patients for the RAPID-MI-ICE

(Rapid Intravascular Cooling in Myocardial Infarction as Adjunctive to

Percutaneous Coronary Intervention) clinical study, which is expected

to enroll approximately 20 patients who present within six hours of

their hea
'/>"/>